Dr. Chapin on Impact of Active Surveillance in Field of Prostate Cancer

Brian F. Chapin, MD
Published: Friday, Apr 21, 2017



Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses impact of active surveillance in the field of prostate cancer.

There has been a large, national increase in the number of patients going onto active surveillance programs, Chapin explains. Compared with the smaller proportion seen previously, researchers now are seeing that up to 40% of men who are diagnosed with low-risk tumors are going onto an active surveillance program.

Additionally, he says, the community is recognizing that not all prostate cancers are the same. Some prostate cancers are indolent and are unlikely to cause significant problems. Patients are becoming more aware of that; therefore, they are seeking out other options and not just choosing to go with active treatment.


Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses impact of active surveillance in the field of prostate cancer.

There has been a large, national increase in the number of patients going onto active surveillance programs, Chapin explains. Compared with the smaller proportion seen previously, researchers now are seeing that up to 40% of men who are diagnosed with low-risk tumors are going onto an active surveillance program.

Additionally, he says, the community is recognizing that not all prostate cancers are the same. Some prostate cancers are indolent and are unlikely to cause significant problems. Patients are becoming more aware of that; therefore, they are seeking out other options and not just choosing to go with active treatment.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x